SIGMOLECS®
for MSK disorders
The 500 Line, engineered to restore mobility and joint strength, has been developed to address unmet clinical needs in acute and chronic MSK disorders through non-invasive, rapid-acting formulations.
Composed of three different Medical Devices (AI500, CR500, ST500) formulated as hydrogel monodoses in a 1.5 mL single-dose vial, with sodium hyaluronate mixed with peptides. The 500 Line is powered by SIGMOLECS®, one of the most innovative concepts available for optimum joint and soft tissue wellness.
The content of the vial must be squeezed to the centre of a surgical patch and applied to the target area.
Advantages of the 500 Line, powered by SIGMOLECS®:
INNOVATIVE
Sodium hyaluronate mixed with a sequence of specific peptides’ chains.
TARGETED
Local action
PRECLINICALLY TESTED
In vitro, ex-vivo and in-vivo
CLINICALLY PROVEN
Safe and effective
SIGMOLECS®
The 500 Line - Usage Guide video
AI500™
Monodose Gel
AI500 GEL is designed to provide relief from myalgia and joint pain.
The formula can improve the movement and function of muscles, joints, and tendons, resulting in greater mobility and flexibility, which helps reduce stiffness and pain.
CLINICAL EVIDENCE
CR500™
Monodose Gel
CR500 GEL is designed to counteract cartilage degeneration, a common condition in osteoarthritic processes.
The formula aims to reduce the degeneration of cartilage associated with osteoarthritis, providing protection against joint damage and slowing its progression, ultimately leading to pain relief and improved joint function.
CLINICAL EVIDENCE
ST500™
Monodose Gel
ST500 GEL is developed to help and limit the physiological degeneration of tendons, ligaments, and soft tissues.
It also supports joint function.
CLINICAL EVIDENCE
Join our business
We welcome new partnerships with companies, who are willing to market our products in different countries. Contact us
